Related content

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

By                

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 377-383

Spandidos Publications

Access to resources Recommend Favorite

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

By            

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 253-260

Spandidos Publications

Access to resources Recommend Favorite

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

By              

International Journal of Oncology, Vol. 40, Iss. 4, 2012-01 ,pp. : 1259-1266

Spandidos Publications

Access to resources Recommend Favorite